{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T09:06:36Z","timestamp":1780131996812,"version":"3.54.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T00:00:00Z","timestamp":1777766400000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"AstraZeneca China"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s11523-026-01217-0","type":"journal-article","created":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T07:36:47Z","timestamp":1777793807000},"page":"385-398","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Treatment Patterns and Clinical Outcomes Among Chinese Patients with Stage III NSCLC: The MOOREA Study"],"prefix":"10.1007","volume":"21","clinical-trial-number":[{"clinical-trial-number":"nct04023812","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9146-3048","authenticated-orcid":false,"given":"Ligang","family":"Xing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinming","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangjiao","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yubiao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuangying","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongqing","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lujun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingcheng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimin","family":"Zang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naixin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baisong","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolong","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anhui","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junfeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuo-Lin","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,3]]},"reference":[{"issue":"3","key":"1217_CR1","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3760\/cma.j.cn112152-20240119-00035","volume":"46","author":"RS Zheng","year":"2024","unstructured":"Zheng RS, Chen R, Han BF, Wang SM, Li L, Sun KX, et al. Cancer incidence and mortality in China, 2022. Zhonghua Zhong Liu Za Zhi. 2024;46(3):221\u201331. https:\/\/doi.org\/10.3760\/cma.j.cn112152-20240119-00035.","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"issue":"1","key":"1217_CR2","doi-asserted-by":"publisher","first-page":"506","DOI":"10.21037\/tlcr.2020.03.40","volume":"10","author":"A Casal-Mourino","year":"2021","unstructured":"Casal-Mourino A, Ruano-Ravina A, Lorenzo-Gonzalez M, Rodriguez-Martinez A, Giraldo-Osorio A, Varela-Lema L, et al. Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival. Transl Lung Cancer Res. 2021;10(1):506\u20135118. https:\/\/doi.org\/10.21037\/tlcr.2020.03.40.","journal-title":"Transl Lung Cancer Res"},{"issue":"11","key":"1217_CR3","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1016\/j.jtho.2023.08.011","volume":"18","author":"Y Li","year":"2023","unstructured":"Li Y, Juergens RA, Finley C, Swaminath A. Current and future treatment options in the management of stage III NSCLC. J Thorac Oncol. 2023;18(11):1478\u201391. https:\/\/doi.org\/10.1016\/j.jtho.2023.08.011.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"1217_CR4","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.chest.2016.10.010","volume":"151","author":"FC Detterbeck","year":"2017","unstructured":"Detterbeck FC, Boffa DJ, Kim AW, Tanoue LT. The eighth edition lung cancer stage classification. Chest. 2017;151(1):193\u2013203. https:\/\/doi.org\/10.1016\/j.chest.2016.10.010.","journal-title":"Chest"},{"issue":"12","key":"1217_CR5","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1200\/JCO.21.01308","volume":"40","author":"DR Spigel","year":"2022","unstructured":"Spigel DR, Faivre-Finn C, Gray JE, Vicente D, Planchard D, Paz-Ares L, et al. Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. J Clin Oncol. 2022;40(12):1301\u201311. https:\/\/doi.org\/10.1200\/JCO.21.01308.","journal-title":"J Clin Oncol"},{"key":"1217_CR6","doi-asserted-by":"publisher","unstructured":"Oncology Society of Chinese Medical A. Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2025 edition). Zhonghua Yi Xue Za Zhi. 2025;105(34):2918\u201359. https:\/\/doi.org\/10.3760\/cma.j.cn112137-20250511-01152","DOI":"10.3760\/cma.j.cn112137-20250511-01152"},{"issue":"4","key":"1217_CR7","doi-asserted-by":"publisher","first-page":"249","DOI":"10.6004\/jnccn.2204.0023","volume":"22","author":"GJ Riely","year":"2024","unstructured":"Riely GJ, Wood DE, Ettinger DS, Aisner DL, Akerley W, Bauman JR, et al. Non-small cell lung cancer, version 4.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2024;22(4):249\u201374. https:\/\/doi.org\/10.6004\/jnccn.2204.0023.","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"1217_CR8","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jtho.2022.10.003","volume":"18","author":"N Girard","year":"2023","unstructured":"Girard N, Bar J, Garrido P, Garassino MC, McDonald F, Mornex F, et al. Treatment characteristics and real-world progression-free survival in patients with unresectable stage III NSCLC who received durvalumab after chemoradiotherapy: findings from the PACIFIC-R study. J Thorac Oncol. 2023;18(2):181\u201393. https:\/\/doi.org\/10.1016\/j.jtho.2022.10.003.","journal-title":"J Thorac Oncol"},{"issue":"4_Suppl","key":"1217_CR9","doi-asserted-by":"publisher","first-page":"S1624","DOI":"10.1016\/j.annonc.2024.10.643","volume":"35","author":"Y-L Wu","year":"2024","unstructured":"Wu Y-L, Wang L, Sendur MAN, Kim Y-C, Zhu Z, Cheng Y, et al. PACIFIC-5: phase III study of consolidation durvalumab in patients with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy. Ann Oncol. 2024;35(4_Suppl):S1624. https:\/\/doi.org\/10.1016\/j.annonc.2024.10.643.","journal-title":"Ann Oncol"},{"issue":"7","key":"1217_CR10","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1056\/NEJMoa2402614","volume":"391","author":"S Lu","year":"2024","unstructured":"Lu S, Kato T, Dong X, Ahn MJ, Quang LV, Soparattanapaisarn N, et al. Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC. N Engl J Med. 2024;391(7):585\u201397. https:\/\/doi.org\/10.1056\/NEJMoa2402614.","journal-title":"N Engl J Med"},{"issue":"21","key":"1217_CR11","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","volume":"386","author":"PM Forde","year":"2022","unstructured":"Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386(21):1973\u201385. https:\/\/doi.org\/10.1056\/NEJMoa2202170.","journal-title":"N Engl J Med"},{"issue":"10308","key":"1217_CR12","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","volume":"398","author":"E Felip","year":"2021","unstructured":"Felip E, Altorki N, Zhou C, Csoszi T, Vynnychenko I, Goloborodko O, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2021;398(10308):1344\u201357. https:\/\/doi.org\/10.1016\/S0140-6736(21)02098-5.","journal-title":"Lancet"},{"issue":"18","key":"1217_CR13","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","volume":"383","author":"YL Wu","year":"2020","unstructured":"Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2020;383(18):1711\u201323. https:\/\/doi.org\/10.1056\/NEJMoa2027071.","journal-title":"N Engl J Med"},{"issue":"14","key":"1217_CR14","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1056\/NEJMoa2310532","volume":"390","author":"YL Wu","year":"2024","unstructured":"Wu YL, Dziadziuszko R, Ahn JS, Barlesi F, Nishio M, Lee DH, et al. Alectinib in resected ALK-positive non-small-cell lung cancer. N Engl J Med. 2024;390(14):1265\u201376. https:\/\/doi.org\/10.1056\/NEJMoa2310532.","journal-title":"N Engl J Med"},{"issue":"18","key":"1217_CR15","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","volume":"389","author":"JV Heymach","year":"2023","unstructured":"Heymach JV, Harpole D, Mitsudomi T, Taube JM, Galffy G, Hochmair M, et al. Perioperative durvalumab for resectable non-small-cell lung cancer. N Engl J Med. 2023;389(18):1672\u201384. https:\/\/doi.org\/10.1056\/NEJMoa2304875.","journal-title":"N Engl J Med"},{"issue":"6","key":"1217_CR16","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1056\/NEJMoa2302983","volume":"389","author":"H Wakelee","year":"2023","unstructured":"Wakelee H, Liberman M, Kato T, Tsuboi M, Lee SH, Gao S, et al. Perioperative pembrolizumab for early-stage non-small-cell lung cancer. N Engl J Med. 2023;389(6):491\u2013503. https:\/\/doi.org\/10.1056\/NEJMoa2302983.","journal-title":"N Engl J Med"},{"issue":"3","key":"1217_CR17","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1001\/jama.2023.24735","volume":"331","author":"S Lu","year":"2024","unstructured":"Lu S, Zhang W, Wu L, Wang W, Zhang P, Neotorch I, et al. Perioperative toripalimab plus chemotherapy for patients with resectable non-small cell lung cancer: the Neotorch randomized clinical trial. JAMA. 2024;331(3):201\u201311. https:\/\/doi.org\/10.1001\/jama.2023.24735.","journal-title":"JAMA"},{"issue":"19","key":"1217_CR18","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1056\/NEJMoa2311926","volume":"390","author":"T Cascone","year":"2024","unstructured":"Cascone T, Awad MM, Spicer JD, He J, Lu S, Sepesi B, et al. Perioperative nivolumab in resectable lung cancer. N Engl J Med. 2024;390(19):1756\u201369. https:\/\/doi.org\/10.1056\/NEJMoa2311926.","journal-title":"N Engl J Med"},{"issue":"2_Suppl","key":"1217_CR19","doi-asserted-by":"publisher","first-page":"S1299","DOI":"10.1016\/j.annonc.2023.10.054","volume":"34","author":"D Yue","year":"2023","unstructured":"Yue D, Wang W, Liu H, Chen Q, Chen C, Zhang J, et al. LBA58 Pathological response to neoadjuvant tislelizumab (TIS) plus platinum-doublet (PtDb) chemotherapy (CT) in resectable stage II-IIIA NSCLC patients (pts) in the phase III (Ph3) RATIONALE-315 trial. Ann Oncol. 2023;34(2_Suppl):S1299. https:\/\/doi.org\/10.1016\/j.annonc.2023.10.054.","journal-title":"Ann Oncol"},{"issue":"3","key":"1217_CR20","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.annonc.2024.01.005","volume":"35","author":"D Yue","year":"2024","unstructured":"Yue D, Wang W, Liu H, Chen Q, Chen C, Zhang J, et al. VP1-2024: RATIONALE-315: event-free survival (EFS) and overall survival (OS) of neoadjuvant tislelizumab (TIS) plus chemotherapy (CT) with adjuvant TIS in resectable non-small cell lung cancer (NSCLC). Ann Oncol. 2024;35(3):332\u20133. https:\/\/doi.org\/10.1016\/j.annonc.2024.01.005.","journal-title":"Ann Oncol"},{"issue":"10","key":"1217_CR21","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1016\/j.jtho.2021.05.003","volume":"16","author":"AR Jazieh","year":"2021","unstructured":"Jazieh AR, Onal HC, Tan DSW, Soo RA, Prabhash K, Kumar A, et al. Real-world treatment patterns and clinical outcomes in patients with Stage III NSCLC: results of KINDLE, a multicountry observational study. J Thorac Oncol. 2021;16(10):1733\u201344. https:\/\/doi.org\/10.1016\/j.jtho.2021.05.003.","journal-title":"J Thorac Oncol"},{"key":"1217_CR22","unstructured":"Wenzhao Z, Group CTO, Cancer CSoL, Association LCGoOBCM, Multidisciplinary Team Diagnosis and Treatment Committee CMDA, Yilong W. Chinese expert consensus on the multidisciplinary team diagnosis and treatment of lung cancer. Zhonghua Zhong Liu Za Zhi. 2020;42(10):817\u201328."},{"issue":"5 Suppl","key":"1217_CR23","doi-asserted-by":"publisher","first-page":"7S","DOI":"10.1378\/chest.12-2377","volume":"143","author":"FC Detterbeck","year":"2013","unstructured":"Detterbeck FC, Lewis SZ, Diekemper R, Addrizzo-Harris D, Alberts WM. Executive summary: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):7S-37S. https:\/\/doi.org\/10.1378\/chest.12-2377.","journal-title":"Chest"},{"issue":"6","key":"1217_CR24","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1111\/ajco.13938","volume":"19","author":"U Batra","year":"2023","unstructured":"Batra U, Prabhash K, Agarwal JP, Darlong L, Munshi A, Penumadu P, et al. Clinical management of Stage III non-small cell lung cancer in India: an expert consensus statement. Asia Pac J Clin Oncol. 2023;19(6):606\u201317. https:\/\/doi.org\/10.1111\/ajco.13938.","journal-title":"Asia Pac J Clin Oncol"},{"issue":"1","key":"1217_CR25","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s12094-019-02134-7","volume":"22","author":"M Majem","year":"2020","unstructured":"Majem M, Hernandez-Hernandez J, Hernando-Trancho F, Rodriguez de Dios N, Sotoca A, Trujillo-Reyes JC, et al. Multidisciplinary consensus statement on the clinical management of patients with stage III non-small cell lung cancer. Clin Transl Oncol. 2020;22(1):21\u201336. https:\/\/doi.org\/10.1007\/s12094-019-02134-7.","journal-title":"Clin Transl Oncol"},{"key":"1217_CR26","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.lungcan.2021.05.025","volume":"158","author":"E Goker","year":"2021","unstructured":"Goker E, Altwairgi A, Al-Omair A, Tfayli A, Black E, Elsayed H, et al. Multi-disciplinary approach for the management of non-metastatic non-small cell lung cancer in the Middle East and Africa: expert panel recommendations. Lung Cancer. 2021;158:60\u201373. https:\/\/doi.org\/10.1016\/j.lungcan.2021.05.025.","journal-title":"Lung Cancer"},{"issue":"Supplement","key":"1217_CR27","doi-asserted-by":"publisher","first-page":"S46","DOI":"10.4103\/ijc.IJC_51_21","volume":"59","author":"U Batra","year":"2022","unstructured":"Batra U, Munshi A, Kabra V, Momi G. Relevance of multi-disciplinary team approach in diagnosis and management of Stage III NSCLC. Indian J Cancer. 2022;59(Supplement):S46\u201355. https:\/\/doi.org\/10.4103\/ijc.IJC_51_21.","journal-title":"Indian J Cancer"},{"issue":"24","key":"1217_CR28","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","volume":"379","author":"SJ Antonia","year":"2018","unstructured":"Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Overall survival with durvalumab after chemoradiotherapy in Stage III NSCLC. N Engl J Med. 2018;379(24):2342\u201350. https:\/\/doi.org\/10.1056\/NEJMoa1809697.","journal-title":"N Engl J Med"},{"issue":"11","key":"1217_CR29","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/S1470-2045(20)30453-8","volume":"21","author":"M Provencio","year":"2020","unstructured":"Provencio M, Nadal E, Insa A, Garcia-Campelo MR, Casal-Rubio J, Domine M, et al. Neoadjuvant chemotherapy and Nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020;21(11):1413\u201322. https:\/\/doi.org\/10.1016\/S1470-2045(20)30453-8.","journal-title":"Lancet Oncol"},{"issue":"26","key":"1217_CR30","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1200\/JCO.21.00276","volume":"39","author":"SI Rothschild","year":"2021","unstructured":"Rothschild SI, Zippelius A, Eboulet EI, Savic Prince S, Betticher D, Bettini A, et al. SAKK 16\/14: Durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small-cell lung cancer-a multicenter single-arm phase II trial. J Clin Oncol. 2021;39(26):2872\u201380. https:\/\/doi.org\/10.1200\/JCO.21.00276.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1217_CR31","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/S1470-2045(17)30729-5","volume":"19","author":"WZ Zhong","year":"2018","unstructured":"Zhong WZ, Wang Q, Mao WM, Xu ST, Wu L, Shen Y, et al. Gefitinib versus Vinorelbine plus Cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT\/CTONG1104): a randomised, open-label, phase 3 study. Lancet Oncol. 2018;19(1):139\u201348. https:\/\/doi.org\/10.1016\/S1470-2045(17)30729-5.","journal-title":"Lancet Oncol"},{"issue":"9","key":"1217_CR32","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/S2213-2600(21)00134-X","volume":"9","author":"J He","year":"2021","unstructured":"He J, Su C, Liang W, Xu S, Wu L, Fu X, et al. Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial. Lancet Respir Med. 2021;9(9):1021\u20139. https:\/\/doi.org\/10.1016\/S2213-2600(21)00134-X.","journal-title":"Lancet Respir Med"},{"issue":"11","key":"1217_CR33","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/S2213-2600(18)30277-7","volume":"6","author":"D Yue","year":"2018","unstructured":"Yue D, Xu S, Wang Q, Li X, Shen Y, Zhao H, et al. Erlotinib versus Vinorelbine plus Cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial. Lancet Respir Med. 2018;6(11):863\u201373. https:\/\/doi.org\/10.1016\/S2213-2600(18)30277-7.","journal-title":"Lancet Respir Med"},{"issue":"3","key":"1217_CR34","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.jtho.2019.10.022","volume":"15","author":"WL Tan","year":"2020","unstructured":"Tan WL, Chua KLM, Lin CC, Lee VHF, Tho LM, Chan AW, et al. Asian Thoracic Oncology Research Group expert consensus statement on optimal management of stage III NSCLC. J Thorac Oncol. 2020;15(3):324\u201343. https:\/\/doi.org\/10.1016\/j.jtho.2019.10.022.","journal-title":"J Thorac Oncol"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01217-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-026-01217-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01217-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T08:54:59Z","timestamp":1780131299000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-026-01217-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1217"],"URL":"https:\/\/doi.org\/10.1007\/s11523-026-01217-0","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"7 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by AstraZeneca China (no grant number).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Ligang Xing, Jinming Yu, Xiangjiao Meng, Ren Zhao, Weihua Yang, Yubiao Guo, Juan Li, Min Fan, Chuangying Xiao, Yanping Ren, Lihua Dong, Dongqing Lv, Lujun Zhao, Yingcheng Lin, Xiaotao Zhang, Long Chen, Ye Wang, Yuhui Zhang, Aimin Zang, Gregory Cheng, Anwen Liu, Naixin Liang, Baisong Lou, Jun Wang, Xiaolong Fu, Anhui Shi, Ning Xu, Junfeng Liu, and Zuo-Lin Xiang declare that they have no conflicts of interest that might be relevant to the contents of this manuscript. All authors have completed and submitted the International Committee of Medical Journal Editors Form for Disclosure of Potential Conflicts of Interest, and none were reported.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest Disclosures"}},{"value":"This study was performed in accordance with the ethical principles of the Declaration of Helsinki that are consistent with International Council for Harmonisation\/Good Clinical Practice, applicable regulatory requirements, and the AstraZeneca policy on Bioethics. The Clinical Study Protocol was submitted to the Institutional Review Board or Independent Ethics Committee for review and approval.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Before any study-specific procedures were performed, the investigator at each site obtained a signed and dated informed consent form (ICF) from each participant. The investigator ensured that patients were provided with full and adequate oral and written information about the nature, purpose, potential risks, and benefits of the study. Patients were explicitly informed of their right to discontinue participation in the study at any time. They were also given the opportunity to ask questions and allowed sufficient time to consider the information provided. The investigator stored the original signed ICF, and either the signed original or a copy of it was given to the patient.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"All authors confirm that they have read and approved the manuscript; no eligible authors are omitted. The article has not been previously published nor is it under consideration for publication elsewhere. It has been approved by relevant authorities. If accepted, it will not be published elsewhere in any form without the written consent of the copyright holder.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Data underlying the findings described in this manuscript may be obtained in accordance with AstraZeneca\u2019s data sharing policy.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Conceptualization: Ligang Xing and Jinming Yu. Data curation: Ligang Xing, Jinming Yu, Xiangjiao Meng, Ren Zhao, Weihua Yang, Yubiao Guo, Juan Li, Min Fan, Chuangying Xiao, Yanping Ren, Lihua Dong, Dongqing Lv, Lujun Zhao, Yingcheng Lin, Xiaotao Zhang, Long Chen, Ye Wang, Yuhui Zhang, Aimin. Zang, Gregory Cheng, Anwen Liu, Naixin Liang, Baisong Lou, Jun Wang, Xiaolong Fu, Anhui Shi, Ning Xu, Junfeng Liu, and Zuo-Lin Xiang. Formal analysis: Xiangjiao Meng, Ligang Xing, and Yubiao Guo. Funding acquisition: Ligang Xing and Jinming Yu. Investigation: Ligang Xing, Jinming Yu, Xiangjiao Meng, Ren Zhao, Weihua Yang, Yubiao Guo, Juan Li, Min Fan6, Chuangying Xiao, Yanping Ren, Lihua Dong, Dongqing Lv, Lujun Zhao, Yingcheng Lin, Xiaotao Zhang, Long Chen, Ye Wang, Yuhui Zhang, Aimin. Zang, Gregory Cheng, Anwen Liu, Naixin Liang, Baisong Lou, Jun Wang, Xiaolong Fu, Anhui Shi, Ning Xu, Junfeng Liu, and Zuo-Lin Xiang. Methodology: Juan Li. Project administration: Xiangjiao Meng, Ligang Xing, and Min Fan. Resources: Chuangying Xiao. Software: Yanping Ren. Supervision: Jinming Yu and Lihua Dong. Validation: Xiangjiao Meng, Ligang Xing, and Jinming Yu. Visualization: Lujun Zhao. Writing\u2014original draft: Xiangjiao Meng, Ligang Xing, and Dongqing Lv. Writing\u2014review and editing: Ligang Xing, Jinming Yu, and Weihua Yang.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}